> top > docs > PubMed:26215578 > annotations

PubMed:26215578 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 0-10 D066260 denotes Epiregulin
T2 0-10 D066260 denotes Epiregulin
T3 26-32 UBERON:0000310 denotes breast
T4 33-46 D063646 denotes tumorigenesis
T5 33-46 D063646 denotes tumorigenesis
T6 66-72 UBERON:0027368 denotes matrix
T8 66-92 Q11133 denotes matrix metalloproteinase 1
T10 66-92 P21692 denotes matrix metalloproteinase 1
T11 66-92 P81563 denotes matrix metalloproteinase 1
T12 66-92 Q8GWW6 denotes matrix metalloproteinase 1
T14 66-92 PR:000010469 denotes matrix metalloproteinase 1
T15 66-92 Q9XSZ5 denotes matrix metalloproteinase 1
T16 66-92 P28053 denotes matrix metalloproteinase 1
T17 66-92 P13943 denotes matrix metalloproteinase 1
T18 66-92 P03956 denotes matrix metalloproteinase 1
T13 66-92 D020781 denotes matrix metalloproteinase 1
T7 66-92 GO:0004232 denotes matrix metalloproteinase 1
T9 66-92 GO:0051405 denotes matrix metalloproteinase 1
T20 138-154 UBERON:0000021 denotes epidermal growth
T23 138-161 Q9GU69 denotes epidermal growth factor
T21 138-161 D004815 denotes epidermal growth factor
T22 138-161 D004815 denotes epidermal growth factor
T24 138-161 GO:0005154 denotes epidermal growth factor
T30 163-166 Q95ND4 denotes EGF
T32 163-166 PR:P01133 denotes EGF
T33 163-166 P01133 denotes EGF
T34 163-166 PR:P07522 denotes EGF
T35 163-166 PR:P01132 denotes EGF
T36 163-166 Q9BEA0 denotes EGF
T37 163-166 P01132 denotes EGF
T38 163-166 P07522 denotes EGF
T40 163-166 PR:000006928 denotes EGF
T41 163-166 P26224 denotes EGF
T43 163-166 Q00968 denotes EGF
T31 163-166 CHEBI:140739 denotes EGF
T42 163-166 D004815 denotes EGF
T44 163-166 D004815 denotes EGF
T39 163-166 GO:0005154 denotes EGF
T45 178-185 CHEBI:52214 denotes ligands
T46 219-225 UBERON:0000310 denotes breast
T47 219-232 D001943 denotes breast cancer
T48 219-232 D001943 denotes breast cancer
T49 290-293 Q95ND4 denotes EGF
T51 290-293 PR:P01133 denotes EGF
T52 290-293 P01133 denotes EGF
T53 290-293 PR:P07522 denotes EGF
T54 290-293 PR:P01132 denotes EGF
T55 290-293 Q9BEA0 denotes EGF
T56 290-293 P01132 denotes EGF
T57 290-293 P07522 denotes EGF
T59 290-293 PR:000006928 denotes EGF
T60 290-293 P26224 denotes EGF
T62 290-293 Q00968 denotes EGF
T50 290-293 CHEBI:140739 denotes EGF
T61 290-293 D004815 denotes EGF
T63 290-293 D004815 denotes EGF
T58 290-293 GO:0005154 denotes EGF
T64 301-308 CHEBI:52214 denotes ligands
T65 332-338 UBERON:0000310 denotes breast
T66 332-345 D001943 denotes breast cancer
T67 332-345 D001943 denotes breast cancer
T68 411-418 CHEBI:52214 denotes ligands
T69 428-434 UBERON:0000310 denotes breast
T70 428-440 D001943 denotes breast tumor
T71 428-440 D001943 denotes breast tumor
T74 512-515 Q95ND4 denotes EGF
T76 512-515 PR:P01133 denotes EGF
T77 512-515 P01133 denotes EGF
T78 512-515 PR:P07522 denotes EGF
T79 512-515 PR:P01132 denotes EGF
T80 512-515 Q9BEA0 denotes EGF
T81 512-515 P01132 denotes EGF
T82 512-515 P07522 denotes EGF
T84 512-515 PR:000006928 denotes EGF
T85 512-515 P26224 denotes EGF
T87 512-515 Q00968 denotes EGF
T75 512-515 CHEBI:140739 denotes EGF
T86 512-515 D004815 denotes EGF
T88 512-515 D004815 denotes EGF
T83 512-515 GO:0005154 denotes EGF
T89 530-540 D066260 denotes epiregulin
T90 530-540 D066260 denotes epiregulin
T91 542-546 PR:000007171 denotes EREG
T92 542-546 PR:O14944 denotes EREG
T93 542-546 PR:Q61521 denotes EREG
T94 542-546 PR:Q9Z0L5 denotes EREG
T95 577-583 UBERON:0000310 denotes breast
T96 584-597 D063646 denotes tumorigenesis
T97 584-597 D063646 denotes tumorigenesis
T98 608-612 PR:000007171 denotes EREG
T99 608-612 PR:O14944 denotes EREG
T100 608-612 PR:Q61521 denotes EREG
T101 608-612 PR:Q9Z0L5 denotes EREG
T102 668-673 D006801 denotes human
T105 685-709 D002285 denotes ductal carcinoma in situ
T106 685-709 D002285 denotes ductal carcinoma in situ
T112 711-715 CVCL_5552 denotes DCIS
T111 711-715 D002285 denotes DCIS
T113 711-715 D002285 denotes DCIS
T114 739-742 Q41249 denotes PCR
T115 739-742 O66148 denotes PCR
T116 739-742 Q59987 denotes PCR
T117 739-742 Q01289 denotes PCR
T118 739-742 O80333 denotes PCR
T119 739-742 P15904 denotes PCR
T120 739-742 Q9SDT1 denotes PCR
T121 739-742 Q39617 denotes PCR
T123 809-814 SO:0002031 denotes shRNA
T122 809-814 D034741 denotes shRNA
T124 874-878 PR:000007171 denotes EREG
T125 874-878 PR:O14944 denotes EREG
T126 874-878 PR:Q61521 denotes EREG
T127 874-878 PR:Q9Z0L5 denotes EREG
T129 893-902 CVCL_5552 denotes MCF10DCIS
T130 898-902 D002285 denotes DCIS
T132 898-902 D002285 denotes DCIS
T133 963-967 PR:000007171 denotes EREG
T134 963-967 PR:O14944 denotes EREG
T135 963-967 PR:Q61521 denotes EREG
T136 963-967 PR:Q9Z0L5 denotes EREG
T137 977-982 D009369 denotes tumor
T138 977-982 D009369 denotes tumor
T139 977-987 CL:0001063 denotes tumor cell
T140 1103-1108 D009369 denotes tumor
T141 1103-1108 D009369 denotes tumor
T142 1159-1162 Q95ND4 denotes EGF
T144 1159-1162 PR:P01133 denotes EGF
T145 1159-1162 P01133 denotes EGF
T146 1159-1162 PR:P07522 denotes EGF
T147 1159-1162 PR:P01132 denotes EGF
T148 1159-1162 Q9BEA0 denotes EGF
T149 1159-1162 P01132 denotes EGF
T150 1159-1162 P07522 denotes EGF
T152 1159-1162 PR:000006928 denotes EGF
T153 1159-1162 P26224 denotes EGF
T155 1159-1162 Q00968 denotes EGF
T143 1159-1162 CHEBI:140739 denotes EGF
T154 1159-1162 D004815 denotes EGF
T156 1159-1162 D004815 denotes EGF
T151 1159-1162 GO:0005154 denotes EGF
T157 1179-1183 PR:000007171 denotes EREG
T158 1179-1183 PR:O14944 denotes EREG
T159 1179-1183 PR:Q61521 denotes EREG
T160 1179-1183 PR:Q9Z0L5 denotes EREG
T162 1199-1208 CVCL_5552 denotes MCF10DCIS
T163 1204-1208 D002285 denotes DCIS
T165 1204-1208 D002285 denotes DCIS
T167 1229-1235 CVCL_0598 denotes MCF10A
T168 1232-1235 PR:000002396 denotes 10A
T171 1240-1247 CVCL_5555 denotes MCF10AT
T172 1287-1296 SO:0000119 denotes regulated
T173 1300-1310 CL:0000057 denotes fibroblast
T175 1300-1324 GO:0005104 denotes fibroblast growth factor
T177 1300-1333 Q86PM4 denotes fibroblast growth factor receptor
T178 1300-1333 Q4H3K6 denotes fibroblast growth factor receptor
T180 1300-1333 PR:000001349 denotes fibroblast growth factor receptor
T181 1300-1333 Q26614 denotes fibroblast growth factor receptor
T182 1300-1333 Q95YM9 denotes fibroblast growth factor receptor
T179 1300-1333 D017468 denotes fibroblast growth factor receptor
T188 1335-1339 GO:0005007 denotes FGFR
T189 1359-1363 PR:000007171 denotes EREG
T190 1359-1363 PR:O14944 denotes EREG
T191 1359-1363 PR:Q61521 denotes EREG
T192 1359-1363 PR:Q9Z0L5 denotes EREG
T194 1378-1387 CVCL_5552 denotes MCF10DCIS
T195 1383-1387 D002285 denotes DCIS
T197 1383-1387 D002285 denotes DCIS
T198 1411-1416 D009369 denotes tumor
T199 1411-1416 D009369 denotes tumor
T201 1508-1514 CVCL_0598 denotes MCF10A
T202 1511-1514 PR:000002396 denotes 10A
T204 1536-1540 PR:000007171 denotes EREG
T205 1536-1540 PR:O14944 denotes EREG
T206 1536-1540 PR:Q61521 denotes EREG
T207 1536-1540 PR:Q9Z0L5 denotes EREG
T208 1657-1661 PR:000007171 denotes EREG
T209 1657-1661 PR:O14944 denotes EREG
T210 1657-1661 PR:Q61521 denotes EREG
T211 1657-1661 PR:Q9Z0L5 denotes EREG
T212 1670-1679 GO:0023052 denotes signaling
T213 1707-1711 PR:000007171 denotes EREG
T214 1707-1711 PR:O14944 denotes EREG
T215 1707-1711 PR:Q61521 denotes EREG
T216 1707-1711 PR:Q9Z0L5 denotes EREG
T218 1733-1739 CVCL_0598 denotes MCF10A
T219 1736-1739 PR:000002396 denotes 10A
T221 1779-1785 UBERON:0027368 denotes matrix
T223 1779-1805 Q11133 denotes matrix metalloproteinase-1
T225 1779-1805 P21692 denotes matrix metalloproteinase-1
T226 1779-1805 P81563 denotes matrix metalloproteinase-1
T227 1779-1805 Q8GWW6 denotes matrix metalloproteinase-1
T229 1779-1805 PR:000010469 denotes matrix metalloproteinase-1
T230 1779-1805 Q9XSZ5 denotes matrix metalloproteinase-1
T231 1779-1805 P28053 denotes matrix metalloproteinase-1
T232 1779-1805 P13943 denotes matrix metalloproteinase-1
T233 1779-1805 P03956 denotes matrix metalloproteinase-1
T228 1779-1805 D020781 denotes matrix metalloproteinase-1
T222 1779-1805 GO:0004232 denotes matrix metalloproteinase-1
T224 1779-1805 GO:0051405 denotes matrix metalloproteinase-1
T235 1804-1810 PR:O23507 denotes 1 (MMP
T236 1807-1810 CHEBI:340824 denotes MMP
T239 1807-1810 CHEBI:59761 denotes MMP
T241 1807-1812 Q11133 denotes MMP-1
T242 1807-1812 P13943 denotes MMP-1
T243 1807-1812 PR:P03956 denotes MMP-1
T244 1807-1812 P21692 denotes MMP-1
T245 1807-1812 PR:Q8GWW6 denotes MMP-1
T246 1807-1812 P81563 denotes MMP-1
T247 1807-1812 PR:000010469 denotes MMP-1
T248 1807-1812 Q9XSZ5 denotes MMP-1
T249 1807-1812 P28053 denotes MMP-1
T250 1807-1812 PR:Q12372 denotes MMP-1
T251 1807-1812 P03956 denotes MMP-1
T240 1807-1812 GO:0004232 denotes MMP-1
T252 1863-1868 D006801 denotes human
T253 1869-1875 D009369 denotes tumors
T254 1869-1875 D009369 denotes tumors
T256 1888-1892 CVCL_5552 denotes DCIS
T255 1888-1892 D002285 denotes DCIS
T257 1888-1892 D002285 denotes DCIS
T258 1911-1915 PR:000007171 denotes EREG
T259 1911-1915 PR:O14944 denotes EREG
T260 1911-1915 PR:Q61521 denotes EREG
T261 1911-1915 PR:Q9Z0L5 denotes EREG
T262 1920-1923 CHEBI:340824 denotes MMP
T265 1920-1923 CHEBI:59761 denotes MMP
T267 1920-1925 Q11133 denotes MMP-1
T268 1920-1925 P13943 denotes MMP-1
T269 1920-1925 PR:P03956 denotes MMP-1
T270 1920-1925 P21692 denotes MMP-1
T271 1920-1925 PR:Q8GWW6 denotes MMP-1
T272 1920-1925 P81563 denotes MMP-1
T273 1920-1925 PR:000010469 denotes MMP-1
T274 1920-1925 Q9XSZ5 denotes MMP-1
T275 1920-1925 P28053 denotes MMP-1
T276 1920-1925 PR:Q12372 denotes MMP-1
T277 1920-1925 P03956 denotes MMP-1
T266 1920-1925 GO:0004232 denotes MMP-1
T278 1938-1942 PR:000007171 denotes EREG
T279 1938-1942 PR:O14944 denotes EREG
T280 1938-1942 PR:Q61521 denotes EREG
T281 1938-1942 PR:Q9Z0L5 denotes EREG
T283 1958-1962 CVCL_5552 denotes DCIS
T282 1958-1962 D002285 denotes DCIS
T284 1958-1962 D002285 denotes DCIS
T286 1990-2007 UBERON:0008367 denotes breast epithelium
T288 2013-2017 PR:000007171 denotes EREG
T289 2013-2017 PR:O14944 denotes EREG
T290 2013-2017 PR:Q61521 denotes EREG
T291 2013-2017 PR:Q9Z0L5 denotes EREG
T292 2022-2025 CHEBI:340824 denotes MMP
T295 2022-2025 CHEBI:59761 denotes MMP
T297 2022-2027 Q11133 denotes MMP-1
T298 2022-2027 P13943 denotes MMP-1
T299 2022-2027 PR:P03956 denotes MMP-1
T300 2022-2027 P21692 denotes MMP-1
T301 2022-2027 PR:Q8GWW6 denotes MMP-1
T302 2022-2027 P81563 denotes MMP-1
T303 2022-2027 PR:000010469 denotes MMP-1
T304 2022-2027 Q9XSZ5 denotes MMP-1
T305 2022-2027 P28053 denotes MMP-1
T306 2022-2027 PR:Q12372 denotes MMP-1
T307 2022-2027 P03956 denotes MMP-1
T296 2022-2027 GO:0004232 denotes MMP-1
T309 2059-2063 CVCL_5552 denotes DCIS
T308 2059-2063 D002285 denotes DCIS
T310 2059-2063 D002285 denotes DCIS
T311 2144-2151 CHEBI:34922 denotes pathway
T312 2162-2166 PR:000007171 denotes EREG
T313 2162-2166 PR:O14944 denotes EREG
T314 2162-2166 PR:Q61521 denotes EREG
T315 2162-2166 PR:Q9Z0L5 denotes EREG
T316 2171-2174 CHEBI:340824 denotes MMP
T319 2171-2174 CHEBI:59761 denotes MMP
T321 2171-2176 Q11133 denotes MMP-1
T322 2171-2176 P13943 denotes MMP-1
T323 2171-2176 PR:P03956 denotes MMP-1
T324 2171-2176 P21692 denotes MMP-1
T325 2171-2176 PR:Q8GWW6 denotes MMP-1
T326 2171-2176 P81563 denotes MMP-1
T327 2171-2176 PR:000010469 denotes MMP-1
T328 2171-2176 Q9XSZ5 denotes MMP-1
T329 2171-2176 P28053 denotes MMP-1
T330 2171-2176 PR:Q12372 denotes MMP-1
T331 2171-2176 P03956 denotes MMP-1
T320 2171-2176 GO:0004232 denotes MMP-1
T332 2201-2210 GO:0009058 denotes formation
T333 2226-2232 UBERON:0000310 denotes breast
T334 2226-2239 D001943 denotes breast cancer
T335 2226-2239 D001943 denotes breast cancer
T336 2328-2338 D015415 denotes biomarkers
T337 2328-2338 D015415 denotes biomarkers

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-121 DRI_Background denotes Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival.
T2 134-268 DRI_Outcome denotes The epidermal growth factor (EGF) family of ligands has been implicated in promoting breast cancer initiation, growth and progression.
T3 269-484 DRI_Approach denotes The contributions of EGF family ligands and their receptors to breast cancer are complex, and the specific mechanisms through which different ligands regulate breast tumor initiation and growth are not well-defined.
T4 485-598 DRI_Background denotes These studies focus on the EGF family member epiregulin (EREG) as a mediator of early stage breast tumorigenesis.
T5 608-775 DRI_Background denotes EREG expression levels were assessed in both cell lines and human samples of ductal carcinoma in situ (DCIS) using quantitative RT-PCR, ELISA and immunohistochemistry.
T6 776-997 DRI_Background denotes Gene knock-down approaches using shRNA-based strategies were used to determine the requirement of EREG for growth of MCF10DCIS cells in vivo, and for identifying mechanisms through which EREG promotes tumor cell survival.
T7 998-1124 DRI_Background denotes Experiments were performed using a combination of two-dimensional culture, three-dimensional culture and tumor growth in vivo.
T8 1134-1350 DRI_Approach denotes In comparison with other EGF family members, EREG was induced in MCF10DCIS cells compared with MCF10A and MCF10AT cells and its expression was partially regulated by fibroblast growth factor receptor (FGFR) activity.
T9 1351-1481 DRI_Approach denotes Reduced EREG expression in MCF10DCIS cells led to decreased tumor growth in vivo, which was associated with reduced cell survival.
T10 1482-1641 DRI_Background denotes Furthermore, treatment of MCF10A cells with exogenous EREG enhanced cell survival both in three-dimensional culture and in response to chemotherapeutic agents.
T11 1642-1814 DRI_Background denotes Examination of EREG-induced signaling pathways demonstrated that EREG promoted survival of MCF10A cells through regulating expression of matrix metalloproteinase-1 (MMP-1).
T12 1815-1937 DRI_Background denotes To determine the relevance of these findings in human tumors, samples of DCIS were analyzed for EREG and MMP-1 expression.
T13 1938-2072 DRI_Background denotes EREG was induced in DCIS lesions compared to normal breast epithelium, and EREG and MMP-1 were correlated in a subset of DCIS samples.
T14 2086-2240 DRI_Background denotes Together, these studies lead to identification of a novel pathway involving EREG and MMP-1 that contributes to the formation of early stage breast cancer.
T15 2241-2436 DRI_Background denotes Understanding these complex pathways could ultimately lead to the development of novel biomarkers of neoplastic progression and/or new therapeutic strategies for patients with early stage cancer.

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 134-598 BACKGROUND denotes The epidermal growth factor (EGF) family of ligands has been implicated in promoting breast cancer initiation, growth and progression. The contributions of EGF family ligands and their receptors to breast cancer are complex, and the specific mechanisms through which different ligands regulate breast tumor initiation and growth are not well-defined. These studies focus on the EGF family member epiregulin (EREG) as a mediator of early stage breast tumorigenesis.
T2 608-1124 METHODS denotes EREG expression levels were assessed in both cell lines and human samples of ductal carcinoma in situ (DCIS) using quantitative RT-PCR, ELISA and immunohistochemistry. Gene knock-down approaches using shRNA-based strategies were used to determine the requirement of EREG for growth of MCF10DCIS cells in vivo, and for identifying mechanisms through which EREG promotes tumor cell survival. Experiments were performed using a combination of two-dimensional culture, three-dimensional culture and tumor growth in vivo.
T3 1134-2072 RESULTS denotes In comparison with other EGF family members, EREG was induced in MCF10DCIS cells compared with MCF10A and MCF10AT cells and its expression was partially regulated by fibroblast growth factor receptor (FGFR) activity. Reduced EREG expression in MCF10DCIS cells led to decreased tumor growth in vivo, which was associated with reduced cell survival. Furthermore, treatment of MCF10A cells with exogenous EREG enhanced cell survival both in three-dimensional culture and in response to chemotherapeutic agents. Examination of EREG-induced signaling pathways demonstrated that EREG promoted survival of MCF10A cells through regulating expression of matrix metalloproteinase-1 (MMP-1). To determine the relevance of these findings in human tumors, samples of DCIS were analyzed for EREG and MMP-1 expression. EREG was induced in DCIS lesions compared to normal breast epithelium, and EREG and MMP-1 were correlated in a subset of DCIS samples.
T4 2086-2436 CONCLUSIONS denotes Together, these studies lead to identification of a novel pathway involving EREG and MMP-1 that contributes to the formation of early stage breast cancer. Understanding these complex pathways could ultimately lead to the development of novel biomarkers of neoplastic progression and/or new therapeutic strategies for patients with early stage cancer.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26215578-0#0#10#gene2069 163-306 gene2069 denotes EGF) family of ligands has been implicated in promoting breast cancer initiation, growth and progression. The contributions of EGF family ligan
26215578-0#66#92#gene4312 938-1382 gene4312 denotes mechanisms through which EREG promotes tumor cell survival. Experiments were performed using a combination of two-dimensional culture, three-dimensional culture and tumor growth in vivo. RESULTS: In comparison with other EGF family members, EREG was induced in MCF10DCIS cells compared with MCF10A and MCF10AT cells and its expression was partially regulated by fibroblast growth factor receptor (FGFR) activity. Reduced EREG expression in MCF1
26215578-0#33#46#diseaseC0596263 572-597 diseaseC0596263 denotes tage breast tumorigenesis
26215578-12#0#4#gene2069 1938-1942 gene2069 denotes EREG
26215578-12#75#79#gene2069 2013-2017 gene2069 denotes EREG
26215578-12#84#89#gene4312 2022-2027 gene4312 denotes MMP-1
26215578-12#20#24#diseaseC0007124 1958-1962 diseaseC0007124 denotes DCIS
26215578-12#121#125#diseaseC0007124 2059-2063 diseaseC0007124 denotes DCIS
26215578-13#76#80#gene2069 2162-2166 gene2069 denotes EREG
26215578-13#85#90#gene4312 2171-2176 gene4312 denotes MMP-1
26215578-13#128#153#diseaseC2986665 2214-2239 diseaseC2986665 denotes early stage breast cancer
26215578-2#21#24#gene1950 290-293 gene1950 denotes EGF
26215578-2#21#24#gene1950 290-293 gene1950 denotes EGF
26215578-2#63#76#diseaseC0006142 332-345 diseaseC0006142 denotes breast cancer
26215578-2#63#76#diseaseC0678222 332-345 diseaseC0678222 denotes breast cancer
26215578-2#159#171#diseaseC1458155 428-440 diseaseC1458155 denotes breast tumor
26215578-3#27#30#gene1950 512-515 gene1950 denotes EGF
26215578-3#99#112#diseaseC0596263 584-597 diseaseC0596263 denotes tumorigenesis
0#10#gene206933#46#diseaseC0596263 26215578-0#0#10#gene2069 26215578-0#33#46#diseaseC0596263 associated_with "EGF) family of ligands has been implicated in promoting breast cancer initiation, growth and progression. The contributions of EGF family ligan",tage breast tumorigenesis
66#92#gene431233#46#diseaseC0596263 26215578-0#66#92#gene4312 26215578-0#33#46#diseaseC0596263 associated_with "mechanisms through which EREG promotes tumor cell survival. Experiments were performed using a combination of two-dimensional culture, three-dimensional culture and tumor growth in vivo. RESULTS: In comparison with other EGF family members, EREG was induced in MCF10DCIS cells compared with MCF10A and MCF10AT cells and its expression was partially regulated by fibroblast growth factor receptor (FGFR) activity. Reduced EREG expression in MCF1",tage breast tumorigenesis
0#4#gene206920#24#diseaseC0007124 26215578-12#0#4#gene2069 26215578-12#20#24#diseaseC0007124 associated_with EREG,DCIS
0#4#gene2069121#125#diseaseC0007124 26215578-12#0#4#gene2069 26215578-12#121#125#diseaseC0007124 associated_with EREG,DCIS
75#79#gene206920#24#diseaseC0007124 26215578-12#75#79#gene2069 26215578-12#20#24#diseaseC0007124 associated_with EREG,DCIS
75#79#gene2069121#125#diseaseC0007124 26215578-12#75#79#gene2069 26215578-12#121#125#diseaseC0007124 associated_with EREG,DCIS
84#89#gene431220#24#diseaseC0007124 26215578-12#84#89#gene4312 26215578-12#20#24#diseaseC0007124 associated_with MMP-1,DCIS
84#89#gene4312121#125#diseaseC0007124 26215578-12#84#89#gene4312 26215578-12#121#125#diseaseC0007124 associated_with MMP-1,DCIS
76#80#gene2069128#153#diseaseC2986665 26215578-13#76#80#gene2069 26215578-13#128#153#diseaseC2986665 associated_with EREG,early stage breast cancer
85#90#gene4312128#153#diseaseC2986665 26215578-13#85#90#gene4312 26215578-13#128#153#diseaseC2986665 associated_with MMP-1,early stage breast cancer
21#24#gene195063#76#diseaseC0006142 26215578-2#21#24#gene1950 26215578-2#63#76#diseaseC0006142 associated_with EGF,breast cancer
21#24#gene195063#76#diseaseC0678222 26215578-2#21#24#gene1950 26215578-2#63#76#diseaseC0678222 associated_with EGF,breast cancer
21#24#gene1950159#171#diseaseC1458155 26215578-2#21#24#gene1950 26215578-2#159#171#diseaseC1458155 associated_with EGF,breast tumor
21#24#gene195063#76#diseaseC0006142 26215578-2#21#24#gene1950 26215578-2#63#76#diseaseC0006142 associated_with EGF,breast cancer
21#24#gene195063#76#diseaseC0678222 26215578-2#21#24#gene1950 26215578-2#63#76#diseaseC0678222 associated_with EGF,breast cancer
21#24#gene1950159#171#diseaseC1458155 26215578-2#21#24#gene1950 26215578-2#159#171#diseaseC1458155 associated_with EGF,breast tumor
27#30#gene195099#112#diseaseC0596263 26215578-3#27#30#gene1950 26215578-3#99#112#diseaseC0596263 associated_with EGF,tumorigenesis